A worldwide crisis with nitrosamine contamination in medical products began in 2018 [1].In drugs such as angiotensin II receptor blockers (ARBs), ranitidine, met formin, rifampin, rifapentine, and, recently, verenicline, N–nitrosodimethylamine (NDMA) and other nitrosamines have been detected [2,3].Since then, widespread investigations by regulatory agencies, including the Euro pean Medicines Agency (EMA) and United States Food and Drug Administration (US FDA), were undertaken.